TransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Rating of "Moderate Buy" from Analysts

Shares of TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $127.33.

Several equities analysts have recently weighed in on the company. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a report on Tuesday, June 17th. Piper Sandler reiterated an "overweight" rating and set a $145.00 price target (up previously from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Finally, Oppenheimer lifted their price target on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a report on Tuesday, June 17th.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $112.46 on Friday. The stock has a market capitalization of $3.80 billion, a price-to-earnings ratio of 82.69 and a beta of 2.06. The business has a 50-day moving average of $125.49 and a 200-day moving average of $90.46. The company has a debt-to-equity ratio of 1.92, a current ratio of 9.10 and a quick ratio of 8.32. TransMedics Group has a fifty-two week low of $55.00 and a fifty-two week high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.41. The company had revenue of $143.54 million during the quarter, compared to analysts' expectations of $123.39 million. TransMedics Group had a return on equity of 21.88% and a net margin of 10.03%. TransMedics Group's revenue for the quarter was up 48.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.35 EPS. As a group, sell-side analysts predict that TransMedics Group will post 1 earnings per share for the current fiscal year.

Insider Activity at TransMedics Group

In other TransMedics Group news, Director David Weill sold 732 shares of TransMedics Group stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $123.88, for a total value of $90,680.16. Following the completion of the sale, the director owned 12,134 shares in the company, valued at $1,503,159.92. The trade was a 5.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Anil P. Ranganath sold 686 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the transaction, the insider owned 13,955 shares in the company, valued at approximately $1,950,909. The trade was a 4.69% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,418 shares of company stock worth $1,512,613. Corporate insiders own 7.00% of the company's stock.

Hedge Funds Weigh In On TransMedics Group

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC increased its position in shares of TransMedics Group by 44.3% in the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock worth $30,000 after purchasing an additional 135 shares during the period. CWM LLC increased its holdings in TransMedics Group by 20.1% in the 1st quarter. CWM LLC now owns 925 shares of the company's stock valued at $62,000 after buying an additional 155 shares during the period. Campbell Newman Asset Management Inc. increased its holdings in TransMedics Group by 1.4% in the 1st quarter. Campbell Newman Asset Management Inc. now owns 11,619 shares of the company's stock valued at $782,000 after buying an additional 166 shares during the period. Arizona State Retirement System raised its position in shares of TransMedics Group by 1.9% in the 4th quarter. Arizona State Retirement System now owns 9,668 shares of the company's stock valued at $603,000 after buying an additional 184 shares in the last quarter. Finally, Hager Investment Management Services LLC lifted its holdings in shares of TransMedics Group by 38.3% during the 1st quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock worth $50,000 after acquiring an additional 205 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.